


Journal Pre-proof

AsthmaMap: an interactive knowledge repository for mechanisms of asthma

Alexander Mazein, PhD, Olga Ivanova, MSc, Irina Balaur, PhD, Marek Ostaszewski, PhD, Valeriya Berzhitskaya, PhD, Tatiana Serebriyskaya, PhD, Thomas Ligon, PhD, Jan Hasenauer, PhD, Bertrand De Meulder, PhD, Rupert W. Overall, PhD, Ludovic Roy, MSc, Richard G. Knowles, PhD, Craig E. Wheelock, PhD, Sven-Erik Dahlen, MD, PhD, Kian Fan Chung, MD, Ian M. Adcock, PhD, Graham Roberts, DM, Ratko Djukanovic, MD, Johann Pellet, MSc, Piotr Gawron, PhD, Rudi Balling, PhD, Anke H. Maitland-van der Zee, PharmD, PhD, Reinhard Schneider, PhD, Peter J. Sterk, MD, Charles Auffray, PhD, U-BIOPRED Study Group and the eTRIKS Consortium



PII: S0091-6749(20)31707-3

DOI: <https://doi.org/10.1016/j.jaci.2020.11.032>

Reference: YMAI 14866

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 6 August 2020

Revised Date: 17 October 2020

Accepted Date: 10 November 2020

Please cite this article as: Mazein A, Ivanova O, Balaur I, Ostaszewski M, Berzhitskaya V, Serebriyskaya T, Ligon T, Hasenauer J, De Meulder B, Overall RW, Roy L, Knowles RG, Wheelock CE, Dahlen S-E, Chung KF, Adcock IM, Roberts G, Djukanovic R, Pellet J, Gawron P, Balling R, Maitland-van der Zee AH, Schneider R, Sterk PJ, Auffray C, U-BIOPRED Study Group and the eTRIKS Consortium, AsthmaMap: an interactive knowledge repository for mechanisms of asthma, *Journal of Allergy and Clinical Immunology* (2021), doi: <https://doi.org/10.1016/j.jaci.2020.11.032>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 Journal of Allergy and Clinical Immunology
 2 Paradigms & Perspectives

3 **AsthmaMap: an interactive knowledge repository for mechanisms of asthma**

4 Alexander Mazein, PhD^{1,2,3,*}, Olga Ivanova, MSc^{1,4,5}, Irina Balaur, PhD¹, Marek Ostaszewski,
 5 PhD³, Valeriya Berzhitskaya, PhD⁶, Tatiana Serebriyskaya, PhD⁶, Thomas Ligon, PhD⁷, Jan
 6 Hasenauer, PhD⁸, Bertrand De Meulder, PhD¹, Rupert W. Overall, PhD^{9,10}, Ludovic Roy,
 7 MSc¹, Richard G. Knowles, PhD¹¹, Craig E. Wheelock, PhD¹², Sven-Erik Dahlen, MD, PhD¹³,
 8 Kian Fan Chung, MD¹⁴, Ian M. Adcock, PhD¹⁴, Graham Roberts, DM^{15,16}, Ratko Djukanovic,
 9 MD^{17,18}, Johann Pellet, MSc¹, Piotr Gawron, PhD³, Rudi Balling, PhD³, Anke H. Maitland-van
 10 der Zee, PharmD, PhD⁵, Reinhard Schneider, PhD³, Peter J. Sterk, MD⁵, Charles Auffray,
 11 PhD¹, U-BIOPRED Study Group and the eTRIKS Consortium

- 12 1. European Institute for Systems Biology and Medicine, CIRI UMR5308, CNRS-ENS-UCBL-INSERM,
 13 Université de Lyon, 50 Avenue Tony Garnier, 69007 Lyon, France
- 14 2. Institute of Cell Biophysics, Russian Academy of Sciences, 3 Institutskaya Street, Pushchino, Moscow
 15 Region, 142290, Russia
- 16 3. Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 6 Avenue du Swing, L-4367
 17 Belvaux, Luxembourg
- 18 4. Vrije Universiteit Amsterdam, De Boelelaan 1105, 1081 HV Amsterdam, The Netherlands
- 19 5. Respiratory Medicine, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9,
 20 1105 AZ Amsterdam, The Netherlands
- 21 6. Moscow Institute of Physics and Technology, 9 Institutskiy Pereulok, Dolgoprudny, Moscow Region, 141700,
 22 Russia
- 23 7. Faculty of Physics and Center for NanoScience (CeNS), Ludwig-Maximilians-Universität, 80539 München,
 24 Germany
- 25 8. Institute of Computational Biology, Helmholtz Zentrum München, Ingolstädter Landstr. 1, 85764, Neuherberg,
 26 Germany & Faculty of Mathematics and Natural Sciences, University of Bonn, Endenicher Allee 64, 53115,
 27 Bonn
- 28 9. Center for Regenerative Therapies Dresden (CRTD), Technische Universität Dresden, 01307, Dresden,
 29 Germany
- 30 10. German Center for Neurodegenerative Diseases (DZNE) Dresden, 01307, Dresden, Germany
- 31 11. Knowles Consulting, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage SG1 2FX, UK
- 32 12. Division of Physiological Chemistry 2, Department of Medical Biochemistry and Biophysics, Karolinska
 33 Institute, Stockholm, 17177, Sweden
- 34 13. Unit for experimental asthma and allergy research, Institute of Environmental Medicine (IMM), Karolinska
 35 Institutet, Solnavägen 9, 171 65 Solna, Sweden
- 36 14. National Heart & Lung Institute, Imperial College London, London SW3 6LY, UK
- 37 15. University of Southampton, Southampton, UK
- 38 16. NIHR Southampton Biomedical Research Centre, Southampton, UK
- 39 17. Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, University of
 40 Southampton, Southampton, UK
- 41 18. NIHR Southampton Respiratory Biomedical Research Unit, Southampton University Hospital, Southampton,
 42 UK

43
 44 *Corresponding author: Alexander Mazein, Luxembourg Centre for Systems Biomedicine, University of
 45 Luxembourg, 6 Avenue du Swing, L-4367 Belvaux, Luxembourg, +352 661 900 788, alexander.mazein@uni.lu

46 **Conflict of interest statement**

47 PS is a scientific adviser and has an officially non-substantial interest in the start-up company
 48 Breathomix BV that produces eNoses and accompanying cloud algorithms. RB is a founder
 49 and a shareholder of MEGENO S.A. and a shareholder of ITTM S.A. RS is a founder and a
 50 shareholder of MEGENO S.A. and ITTM S.A. KFC has received honoraria for participating in
 51 advisory board meetings of GSK, AstraZeneca, Roche, Novartis, Merck, BI, TEVA and

Shionogi regarding treatments for asthma, chronic obstructive pulmonary disease and chronic cough and has also been remunerated for speaking engagements. RD reports receiving fees for lectures at symposia organised by Novartis, AstraZeneca and TEVA, consultation for TEVA and Novartis as member of advisory boards, and participation in a scientific discussion about asthma organised by GlaxoSmithKline. RD is a co-founder and current consultant and has shares in Synairgen, a University of Southampton spin-out company. AHMZ reports grants and personal fees from Boehringer Ingelheim and GSK, grants from Vertex, personal fees from AstraZeneca, all paid to her institution, and, in a public-private partnership, sponsored by Health Holland matching grants from Boehringer Ingelheim, Breathomix, Fluida, Ortec Logiqcare, Philips, Quantib-U, Smartfish, SODAQ, Thirona, TopMD and Novartis outside the submitted work. SED reports personal fees from AstraZeneca, Boehringer-Ingelheim, Cayman Chemicals, GSK, Novartis, Regeneron, Roche, Sanofi and Teva outside the submitted work.

The remaining authors declare that they have no relevant conflicts of interest.

Keywords

Asthma, disease mechanisms, disease model, knowledge representation, data interpretation, translational medicine

We present the AsthmaMap, a machine- and human-readable representation of mechanisms underlying asthma. This is an open project driven by a community of experts in systems biomedicine, including lung diseases and computational systems biology specialists. The goal of this work is the integration of the existing knowledge from molecular biology, cell biology and medicine on asthma into a molecular and cellular interaction map of the disease to make possible advanced data interpretation, hypothesis generation and validation for many related projects. This map offers an updatable conceptual model of disease mechanisms that can be transformed into executable dynamic models for computational hypothesis testing and predictions.

Since the AsthmaMap project was first announced in a brief editorial¹, it has been evolved into a browsable online resource accessible via <https://asthma-map.org> in which map modules are composed into a single hierarchically-organised system. The map is thus immediately accessible to researchers for data visualisation and hypothesis generation. We describe the structure of the resource and offer video tutorials on the exploration of the underlying network and its application to data mapping.

The rationale of the project

To design prevention and treatment strategies for complex diseases such as asthma, it is necessary to understand its mechanisms and causes. Results from in-depth studies of asthma-related research are scattered across thousands of publications and new findings are constantly reported. To promote effective research, a dedicated resource is required where asthma mechanisms are assembled into a single repository, accessible in both human- and machine-readable formats, verified by domain experts and used for advanced data interpretation and hypothesis generation beyond the current functional analysis approaches.

Recent advances in systems biology have enabled the creation of representations of mechanisms for multiple diseases² including recently published examples for rheumatoid arthritis³, atherosclerosis⁴ and regulated cell death in cancer⁵. These maps are used for modelling, hypothesis generation and validation in a relevant clinical context as reviewed in the Disease Maps community paper² and described in a recent publication about the Atlas of Cancer Signalling Network applied in preclinical studies⁶. Such resources are referred to as “disease maps” and are defined as conceptual models of the corresponding diseases, collections of interconnected signalling, metabolic and gene regulatory processes^{2,7} (<https://disease-maps.org>). The disease maps are literature-based resources, with their backbone established over well-defined hallmarks of a given disease.

A collective effort, initiated within the EU-funded U-BIOPRED project (<https://www.europeanlung.org/en/projects-and-research/projects/u-biopred>) and further developed within the eTRIKS project (<https://www.etriks.org>), has led to the creation of the AsthmaMap resource, a map for a computational description of the mechanisms relevant to asthma development, progression and treatment. The data for the map construction comes from the published biomedical literature and from high-quality pathway databases. The search was focused on mechanisms that exist in the cell types included and have been shown to be part of asthma pathogenesis. The building of the resource is supported by experts in the field of asthma from the Amsterdam University Medical Centers, University of Amsterdam, the National Heart & Lung Institute of Imperial College London, the Karolinska Institute Stockholm and the University of Southampton (<http://asthma-map.org/team>).

Resource architecture

The AsthmaMap consists of three interconnected layers of granularity: *Cellular Interactions* – an overview diagram of the involved cell types and corresponding pathways represented by cytokines and receptors; *Molecular Relations* – a collection of diagrams split according to cell types that can be seen as a single virtual map with an intermediate level of detail; and *Biochemical Mechanisms* – the most detailed layer where information is shown at the level of molecular processes. Each interaction at a lower level is reflected at a higher level. This enables semantic zooming; i.e. the layers of the AsthmaMap represent the same systems, but with more or fewer details shown, depending on the zoom level.

The Cellular Interactions layer (<https://asthma-map.org/ci>) is a summary of the complexity of underlying mechanisms in connection to the cell types and tissues involved. It facilitates discussions with domain experts, and the creation and curation of the AsthmaMap conceptual shape: modules, cell types, receptors, cytokines and other mediators, connected causes and effects.

The Molecular Relations layer (<https://asthma-map.org/mr>) is represented by diagrams for 16 cell types, including the following: dendritic, airway epithelial, macrophage, neutrophil, eosinophil, eosinophil precursor, mast cells, airway smooth muscle, fibroblast, B-cells, Th0, Th2, ILC precursor, ILC2, goblet cells and Treg. The planned development includes adding Th1, Th17 and ILC3 cell types. This layer was assembled using information from the AsthmaMap Cellular Interactions layer and the MetaCore pathway database (<https://portal.genego.com>). Information on selected relevant interactions was reduced and converted to the standard Activity Flow format¹, and compatibility of the resulting modules was ensured for further processing and merging. The representation of the Molecular Relations layer is well-suited for building qualitative Boolean models.

The Biochemical Mechanisms layer (<https://asthma-map.org/bm>) provides detailed definitions for biochemical reactions, essentially encoding the stoichiometric matrix of the network. This is the most detailed and most challenging layer of the AsthmaMap architecture: it requires manual curation and integration of the available information. The Biochemical Mechanisms layer is currently represented by three diagrams: mast cell, eosinophil and eicosanoid modules. It is available in the Process Description format¹ and the focus is on the molecular processes that describe the involved reactants, products and modifiers, such as enzymes or inhibitors. This layer is suited for quantitative mechanistic models, and a mechanistic model of the mast cell in asthma is under development (<https://asthma-map.org/model>).

Online exploration and data visualisation

The MINERVA platform^{8,9} is a tool for web-based visualisation and exploration of maps and allows quick and easy access to the AsthmaMap content. Zooming and navigation are similar to the navigation of Google Maps thanks to the Google Maps API employed by the MINERVA platform⁸. Annotation of the elements is visible in the left panel both for entities (identifiers for metabolites, proteins, genes, phenotypes) and interactions (references to evidence sources). The content of the maps in MINERVA is searchable, and elements found are highlighted by markers of different colours.

To make this resource friendlier for clinical researchers, biologists and data analysts, we offer the following brief video tutorials (<https://asthma-map.org/tutorials>):

1. A demonstration of browsing starting from the Cellular Interactions layer as a top-level view and an entry point to the AsthmaMap.
2. An explanation of how community curation is possible by adding comments directly to the map and thus providing feedback to the map developers.
3. Searching for drug targets in the AsthmaMap via built-in querying of DrugBank (<https://www.drugbank.ca>) and ChEMBL (<https://www.ebi.ac.uk/chembl>).
4. Brief instructions on the upload for visualisation and exploration of custom experimental data. The eicosanoid map and a multi-omics dataset were used for this tutorial⁹.

Outlook

The effort is designed as an open project. The commenting functionality in MINERVA (<https://asthma-map.org/tutorials>) can be used as an entry point for domain experts. Systems biologists and curators are invited to contribute and advance this collection into a reference resource in the area of asthma research.

We consider the map to be a “work in progress” and see it as an evolving resource. The overall framework is designed in a scalable manner to make it easy to maintain and expand the map. For example, cell types such as Th1, Th9, Th17, NKT, ILC17, ILC22 and LT_i shown in the Cellular Interactions layer need to be reflected in the Molecular Relations layer, and the corresponding mechanisms need to be added to the Biochemical Mechanisms layer.

The development of the AsthmaMap in the future will be coordinated with similar projects in the field of allergic diseases, other respiratory diseases and immune-system-related diseases², including the COVID-19 infection for which a large-scale community is fast-

tracking the development of a dedicated disease map¹⁰. This collaboration will lead to the distribution of shared tasks and optimisation of the work for all participants. It is also important for research focused on comorbidities and identification of mechanisms common to several diseases. Ultimately, it is possible that there will be collaborations on topics that at first sight might seem to be less likely related to asthma, e.g. diseases that might share inflammatory profiles with asthma such as rheumatoid arthritis or inflammatory bowel disease. Furthermore, in systems medicine, there is a tendency of moving away from organ-specific diseases towards thinking about the whole-organism level and new disease ontologies.

The AsthmaMap is designed to be useful for biomedical scientists working in asthma as well as clinical scientists working on defining endotypes of asthma towards personalised medicine. It is intended as a reference resource for making sense of otherwise complex omics datasets by integrating and analysing the prior knowledge and newly generated data. We believe this approach will become of clinical value by contributing to the design of clinical decision support systems and its use for allergy- and inflammation-related research in systems medicine and systems pharmacology. It is expected that on the basis of a detailed description of relevant molecular and physiological processes it will be possible to move from ambiguous and imprecise descriptions of asthma phenotypes to evidence-supported descriptions of asthma endotypes via identification and validation of underlying mechanisms specific to various asthma subtypes. Eventually, the AsthmaMap aims to meet the demand for comprehensive phenotyping of single patients by capturing the biological networks that are operational at the individual level. This will serve to deliver more precise and personalized treatments for this prevalent class of chronic diseases.

Funding

Funded in part by the Innovative Medicines Initiative (IMI) funded by the European Union and the European Federation of Pharmaceutical Industry Associations through U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes, n°115010) and eTRIKS (European Translational Information and Knowledge Management Services, IMI n°115446), the French National Center for Scientific Research (CNRS), the European Institute for Systems Biology and Medicine (EISBM) and the Luxembourg Center for Systems Biomedicine (LCSB).

Availability

The AsthmaMap is accessible through <https://asthma-map.org>.

MetaCore License

The MetaCore license was purchased by the CNRS-EISBM team within the eTRIKS project for developing the Molecular Relations layer of the AsthmaMap.

Acknowledgements

The AsthmaMap project progresses in alliance with the efforts of the Disease Maps Community (<https://disease-maps.org>).


References

1. Mazein A, Knowles RG, Adcock I, Chung KF, Wheelock CE, Maitland-van der Zee AH, et al. AsthmaMap: An expert-driven computational representation of disease mechanisms. *Clin Exp Allergy*. 2018;48:916–8.
2. Mazein A, Ostaszewski M, Kuperstein I, Watterson S, Le Novère N, Lefaudeux D, et al. Systems medicine disease maps: community-driven comprehensive representation of disease mechanisms. *Npj Syst Biol Appl*. 2018;4.
3. Singh V, Kalliolias GD, Ostaszewski M, Veyssiere M, Pilalis E, Gawron P, et al. RA-map: building a state-of-the-art interactive knowledge base for rheumatoid arthritis. *Database J Biol Databases Curation*. 2020.
4. Parton A, McGilligan V, Chemaly M, O'Kane M, Watterson S. New models of atherosclerosis and multi-drug therapeutic interventions. *Bioinforma Oxf Engl*. 2019;35:2449–57.
5. Ravel J-M, Monraz Gomez LC, Sompairac N, Calzone L, Zhivotovsky B, Kroemer G, et al. Comprehensive Map of the Regulated Cell Death Signaling Network: A Powerful Analytical Tool for Studying Diseases. *Cancers*. 2020;12.
6. Monraz Gomez LC, Kondratova M, Ravel J-M, Barillot E, Zinovyev A, Kuperstein I. Application of Atlas of Cancer Signalling Network in preclinical studies. *Brief Bioinform*. 2019;20:701–16.
7. Ostaszewski M, Gebel S, Kuperstein I, Mazein A, Zinovyev A, Dogrusoz U, et al. Community-driven roadmap for integrated disease maps. *Brief Bioinform*. 2018.
8. Gawron P, Ostaszewski M, Satagopam V, Gebel S, Mazein A, Kuzma M, et al. MINERVA – a platform for visualization and curation of molecular interaction networks. *NPJ Syst Biol Appl*. 2016;2:16020.
9. De Meulder, B., Lefaudeux, D., Bigler, J., Loza, M. J., Wheelock, C. E., Sousa, A. R., et al. (2015). The first U-BIOPRED blood handprint of severe asthma. *Eur Respir J*, 46(suppl 59), PA4889.
10. Ostaszewski M, Mazein A, Gillespie ME, Kuperstein I, Niarakis A, Hermjakob H, et al. COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms. *Sci Data*. 2020;7:136.


Figure legend

Figure 1. The AsthmaMap resource in MINERVA. **A.** The entry view of the AsthmaMap available for exploration in the MINERVA platform at <https://asthma.uni.lu>. **B.** The default view of a fragment of the eicosanoid production pathway. **C.** The same fragment of the eicosanoid production pathway with multi-omics data mapped. More details and information on the datasets are provided at <https://asthma-map.org/tutorials>.

a



b



c

